KaydedilenlerDerginizi ekleyin

Dergiler / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2010 / Cilt: 44 - Sayı: 2

Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu

Updated Turkish guidelines for the management of psoriasis with biologic agents

Sibel ALPER
Güzide ÖZARMAĞAN
Mehmet Ali GÜRER
Nahide ONSUN
Nilgün ATAKAN
Sayfa
105–112
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
🔖

Bu Makaleye Atıf Yap

ALPER, S., ÖZARMAĞAN, G., GÜRER, M. A., ONSUN, N., ATAKAN, N. (2022). Güncellenmiş Türkiye psoriasis biyolojik ajan kullanım kılavuzu. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 44 - Sayı: 2, 105–112. https://ajindex.com/articles/622044

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Gottlieb AB, Dann F, Menter A: Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008;7:563-72
  2. Fortune DG, Richards HL, Griffiths CE: Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin 2005;23:681-94
  3. Delaporte E: Immune-mediated inflammatory diseases and psoriasis. Ann Dermatol Venereol 2008;135:269-74
  4. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X et al.: The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-9
  5. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7
  6. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4
  7. Fouéré S, Adjadj L, Pawin H: How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol 2005;19:3:2-6
  8. Derkx B, Taminiau J, Radema S et al.: Tumour-necrosis-factor antibody treatment in Crohn’s disease. L.ancet 1993; 342:173-4
  9. Mease PJ, Goffe BS, Metz J, et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000; 356:385-90
  10. Chaudhari U, Romano P, Mulcahy LD et al.: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 2001;357:1842-7
  11. Dharamsi JW, Bhosle M, Balkrishnan R, Yentzer BA, Feldman SR: Using 'number needed to treat' to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-alpha inhibitors fopatients with severe psoriasis. Br J Dermatol 2009; 161:605-16
  12. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D et al: British Association of Dermatologists: British Association of Dermatologists guidelines for use of biological interventions in psoriasis. Br J Dermatol 2005;153:486-97
  13. Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M et al.: German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 2007;299:111-38. 14. aMenter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB et al.: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biolo- gics. J Am Ac